search for




 

Chronic Fatigue in the Elderly
Korean J Clin Geri 2017 Dec;18(2):53-57
Published online December 29, 2017;  https://doi.org/10.15656/kjcg.2017.18.2.53
Copyright © 2017 The Korean Academy of Clinical Geriatrics.

Sun-young Choi

Department of Family Medicine, International St. Mary’s Hospital, Catholic Kwandong University, Incheon, Korea
Received November 7, 2017; Accepted November 13, 2017.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
Fatigue has physical or mental causes and is prevalent in the elderly. Fatigue may be generally categorized as recent (<1 month), prolonged (1∼6 months), or chronic (>6 months). Chronic fatigue syndrome (CFS), as defined by the CDC in 1994 requires fatigue (at least 6 months) that not be caused by other medical conditions, substance abuse within the last 2 years, obesity (BMI≥45) or major psychiatric conditions. Two or more of eight minor findings (1. Postexertional malaise 2. Impaired memory or concentration 3. Sore throat 4. Tender glands 5. Aching or stiff muscles 6. Joint pain 7. Headaches 8. Unrefreshing sleep) must be present. A psychiatric evaluation is essential for patients with chronic or idiopathic fatigue. Most of patients can be diagnosed after a careful examination in primary care. Treatment for recent fatigue should be directed toward the underlying cause or contributing conditions. No single treatment for chronic fatigue is optimal. Every measures include magnesium, L-carnitine and Graded exercise therapy can be considered for patients with chronic fatigue. As with any treatment, the side effects and risk/benefit ratio must be considered.
Keywords : Fatigue, Chronic fatigue syndrome, L-carnitine
References
  1. Hardy SE. Qualities of fatigue and associated chronic conditions among older adults. J Pain Symptom Manage 2010;39:1033-42.
    Pubmed KoreaMed CrossRef
  2. Wick JY, LaFleur J. Fatigue: implications for the elderly. Consult Pharm 2007;22:566-70, 573-4, 576-8.
    Pubmed CrossRef
  3. Bates DW, Schmitt W, Buchwald D, Ware NC, Lee J, Thoyer E, et al. Prevalence of fatigue and chronic fatigue syndrome in a primary care practice. Arch Intern Med 1993;153:2759-65.
    Pubmed CrossRef
  4. Cathebras PJ, Robbins JM, Kirmayer LJ, Hayton BC. Fatigue in primary care: prevalence, psychiatric comorbidity, illness behavior, and outcome. J Gen Intern Med 1992;7:276-86.
    Pubmed CrossRef
  5. David A, Pelosi A, McDonald E, Stephens D, Ledger D, Rathbone R, et al. Tired, weak, or in need of rest: a profile of fatigue among general practice attenders. BMJ 1990;301:1199-202.
    Pubmed KoreaMed CrossRef
  6. Wessely S, Chalder T, Hirsch S, Wallace P, Wright D. The prevalence and morbidity of chronic fatigue and the chronic fatigue syndrome: a prospective primary care study. Am J Public Health 1997;87:1449-55.
    Pubmed KoreaMed CrossRef
  7. Reyes M, Gary HE Jr, Dobbins JG, Randall B, Steele L, Fukuda K, et al. Surveillance for chronic fatigue syndromefour US cities, September 1989 through August 1993. MMWR CDC Surveill Summ 1997;46:1-13.
    Pubmed
  8. Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, et al. A community-based study of chronic fatigue syndrome. Arch Intern Med 1999;159:2129-37.
    Pubmed CrossRef
  9. Bowen J, Pheby D, Charlett A, McNulty C. Chronic fatigue syndrome: a survey of GPs’ attitudes and knowledge. Fam Pract 2005;22:389-93.
    Pubmed CrossRef
  10. Moldofsky H. Sleep, neuroimmune and neuroendocrine functions in fibromyalgia and chronic fatigue syndrome. Adv Neuroimmunol 1995;5:39-56.
    CrossRef
  11. Parker AJ, Wessely S, Cleare AJ. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol Med 2001;31:1331-45.
    Pubmed CrossRef
  12. Racciatti D, Guagnano MT, Vecchiet J, De Remigis PL, Pizzigallo E, Della Vecchia R, et al. Chronic fatigue syndrome:circadian rhythm and hypothalamic-pituitary-adrenal (HPA) axis impairment. Int J Immunopathol Pharmacol 2001;14:11-5.
    Pubmed CrossRef
  13. Markowitz AJ, Rabow MW. Palliative management of fatigue at the close of life: “it feels like my body is just worn out.” JAMA 2007;298:217.
    Pubmed CrossRef
  14. Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM. The revised piper fatigue scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 1998;25:677-84.
    Pubmed
  15. Smets EM, Garssen B, Bonke B, De Haes JC. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-25.
    CrossRef
  16. Stein KD, Martin SC, Hann DM, Jacobsen PB. A multidimensional measure of fatigue for use with cancer patients. Cancer Pract 1998;6:143-52.
    Pubmed CrossRef
  17. Holley SK. Evaluating patient distress from cancer-related fatigue:an instrument development study. Oncol Nurs Forum 2000;27:1425-31.
    Pubmed
  18. Sánchez Rodríguez A, González Maroño C, Sánchez Ledesma M. Chronic fatigue syndrome: a syndrome in search of definition. Rev Clin Esp 2005;205:70-4.
    Pubmed CrossRef
  19. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994;121:953-9.
    Pubmed CrossRef
  20. Fuller-Thomson E, Nimigon J. Factors associated with depression among individuals with chronic fatigue syndrome:findings from a nationally representative survey. Fam Pract 2008;25:414-22.
    Pubmed CrossRef
  21. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994;38:383-92.
    CrossRef
  22. Taillefer SS, Kirmayer LJ, Robbins JM, Lasry JC. Correlates of illness worry in chronic fatigue syndrome. J Psychosom Res 2003;54:331-7.
    CrossRef
  23. Buckley L, MacHale SM, Cavanagh JT, Sharpe M, Deary IJ, Lawrie SM. Personality dimensions in chronic fatigue syndrome and depression. J Psychosom Res 1999;46:395-400.
    CrossRef
  24. Van Geelen SM, Sinnema G, Hermans HJ, Kuis W. Personality and chronic fatigue syndrome: methodological and conceptual issues. Clin Psychol Rev 2007;27:885-903.
    Pubmed CrossRef
  25. Henderson M, Tannock C. Objective assessment of personality disorder in chronic fatigue syndrome. J Psychosom Res 2004;56:251-4.
    CrossRef
  26. Johnson SK, DeLuca J, Natelson BH. Chronic fatigue syndrome:reviewing the research findings. Ann Behav Med 1999;21:258-71.
    Pubmed CrossRef
  27. Salit IE. Precipitating factors for the chronic fatigue syndrome, J Psychiatr Res 1997;31:59-65.
    CrossRef
  28. Lloyd AR. Postinfective fatigue. In: Jason LA, Fennell PA, Taylor RR, editors. Handbook of chronic fatigue syndrome. Hoboken (NJ): John Wiley & Sons; 2003. p. 108-23.
  29. Hatcher S, House A. Life events, difficulties and dilemmas in the onset of chronic fatigue syndrome: a case-control study. Psychol Med 2003;33:1185-92.
    Pubmed CrossRef
  30. Theorell T, Blomkvist V, Lindh G, Evengård B. Critical life events, infections, and symptoms during the year preceding chronic fatigue syndrome (CFS): an examination of CFS patients and subjects with a nonspecific life crisis. Psychosom Med 1999;61:304-10.
    Pubmed CrossRef
  31. Vercoulen JH, Swanink CM, Galama JM, Fennis JF, Jongen PJ, Hommes OR, et al. The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis: the development of a model. J Psychosom Res 1998:45:507-17.
    CrossRef
  32. Moss-Morris R, Petrie KJ, Weinman J. Functioning in chronic fatigue syndrome: do illness perceptions play a regulatory role? Br J Health Psychol 1996;1:15-25.
    CrossRef
  33. Schmaling KD, Smith WR, Buchwald DS. Significant other responses are associated with fatigue and functional status among patients with chronic fatigue syndrome. Psychosom Med 2000;62:444-50.
    Pubmed CrossRef
  34. Stanley I, Salmon P, Peters S. Doctors and social epidemics:the problem of persistent unexplained physical symptoms, including chronic fatigue. Br J Gen Pract 2002;52:355-6.
    Pubmed KoreaMed
  35. Cairns R, Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome. Occup Med (Lond) 2005;55:20-31.
    Pubmed CrossRef
  36. Reyes M, Dobbins JG, Nisenbaum R, Subedar N, Randall B, Reeves W. Chronic fatigue syndrome progression and self-defined recovery: evidence from the CDC surveillance system. J Chronic Fatigue Syndr 1999;5:17-27.
    CrossRef
  37. Saltzstein BJ, Wyshak G, Hubbuch JT, Perry JC. A naturalistic study of the chronic fatigue syndrome among women in primary care. Gen Hosp Psychiatry 1998;20:307-16.
    CrossRef
  38. Powell P, Bentall RP, Nye FJ, Edwards RH. Patient education to encourage graded exercise in chronic fatigue syndrome. 2-year follow-up of randomised controlled trial. Br J Psychiatry 2004;184:142-6.
    Pubmed CrossRef
  39. Hobday RA, Thomas S, O’Donovan A, Murphy M, Pinching AJ. Dietary intervention in chronic fatigue syndrome. J Hum Nutr Diet 2008;21:141-9.
    Pubmed CrossRef
  40. Baicus C, Baicus A. Spirulina did not ameliorate idiopathic chronic fatigue in four N- of-1 randomized controlled trials. Phytother Res 2007;21:570-3.
    Pubmed CrossRef
  41. Mutch BJ, Banister EW. Ammonia metabolism in exercise and fatigue: a review. Med Sci Sport Exerc 1983;15:41-50.
    Pubmed CrossRef
  42. Nybo L, Dalsgaard M, Steensberg A, Møller K, Secher N. Cerebral ammonia uptake and accumulation during prolonged exercise in humans. J Physiol 2005;563(Pt 1):285-90.
    Pubmed KoreaMed CrossRef
  43. Sugino T, Shirai T, Kajimoto Y, Kajimoto O. L-Ornithine supplementation attenuates physical fatigue in healthy volunteers by modulating lipid and amino acid metabolism. Nutr Res 2008;28:738-43.
    Pubmed CrossRef
  44. Maes M, Mihaylova I, Leunis JC. In chronic fatigue syndrome, the decreased levels of omega-3 poly-unsaturated fatty acids are related to lowered serum zinc and defects in T cell activation. NeuroEndocrinol Lett 2005;26:745-51.
    Pubmed
  45. Behan PO, Behan WM. Essential fatty acids in the treatment of post-viral fatigue syndrome. In: Horrobin DF, editor. Omega-6 essential fatty acids: pathophysiology and roles in clinical medicine. New York: Wiley-Liss; 1990.
  46. Behan PO, Behan WM, Horrobin D. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol Scand 1990;82:209-16, 272-82.
    Pubmed CrossRef
  47. Warren G, McKendrick M, Peet M. The role of essential fatty acids in chronic fatigue syndrome. A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebocontrolled treatment study with high dose of EFA. Acta Neurol Scand 1999;99:112-6.
    Pubmed CrossRef
  48. Heukeloma RO, Prinsb JB, Smitsa MG, Bleijenberg G. Influence of melatonin on fatigue severity in patients with chronic fatigue syndrome and late melatonin secretion. Eur J Neurol 2006;13:55-60.
    Pubmed CrossRef
  49. Olson LG, Ambrogetti A, Sutherland DC. A pilot randomized controlled trial of dexamphetamine in patients with chronic fatigue syndrome. Psychosomatics 2003;44:38-43.
    Pubmed CrossRef
  50. Randall DC, Cafferty FH, Shneerson JM, Smith IE, Llewelyn MB, File SE. Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome. J Psychopharmacol 2005;19:647-60.
    Pubmed CrossRef
  51. See DM, Tilles JG. Alpha-interferon treatment of patients with chronic fatigue syndrome. Immunol Invest 1996;25:153-64.
    CrossRef
  52. McKenzie R, O’Fallon A, Dale J, Demitrack M, Sharma G, Deloria M, et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial, JAMA 1998;280:1061-6.
    Pubmed CrossRef
  53. Cleare AJ, Heap E, Malhi GS, Wessely S, O'Keane V, Miell J. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet 1999;353:455-8.
    CrossRef
  54. Blockmans D, Persoons P, Van Houdenhove B, Lejeune M, Bobbaers H. Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study. Am J Med 2003;114:736-41.
    CrossRef
  55. Cox IM, Campbell MJ, Dowson D. Red blood cell magnesium and chronic fatigue syndrome. Lancet 1991;337:757-60.
    CrossRef
  56. Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology 1997;35:16-23.
    CrossRef
  57. Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis:results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 2004;218:103-8.
    Pubmed CrossRef
  58. Malaguarnera M, Gargante MP, Cristaldi E, Colonna V, Messano M, Koverech A, et al. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. Arch Gerontol Geriatr 2008;46:181-90.
    Pubmed CrossRef
  59. Wallman KE, Morton AR, Goodman C, Grove R, Guilfoyle AM. Randomised controlled trial of graded exercise in chronic fatigue syndrome. Med J Aust 2004;180:444-8.
    Pubmed

 

December 2017, 18 (2)